Limits...
Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs.

Schmier JK, Hulme-Lowe CK, Covert DW - Clin Ophthalmol (2014)

Bottom Line: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population.The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011.There were 16,486 eligible beneficiaries.

View Article: PubMed Central - PubMed

Affiliation: Exponent, Alexandria, VA, USA.

ABSTRACT

Purpose: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population.

Methods: The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011. Patients who had one or more adjunctive therapy prescriptions during 24 months of follow-up were included. Patterns of adjunctive therapy use were identified and compared between patients who had one or two fills of the initial adjunctive therapy and those who had three or more.

Results: There were 16,486 eligible beneficiaries. Of these, 5,933 (36%) had one or more adjunctive therapies within 24 months from the start of the PGA, 82% of whom started adjunctive therapy within 12 months. About 28% of patients started adjunctive therapy with a fixed-combination product; 45% of these patients started within the first 30 days. Overall, a large number of patients (42%) required adjunctive therapy within 30 days. Twenty-five percent of patients had only one or two prescriptions of their initial adjunctive therapy; of these patients, 74% discontinued adjunctive therapy altogether.

Conclusion: Approximately 30% of patients starting glaucoma therapy will require adjunctive therapy within 1 year, and many receive a fixed-combination product as initial adjunctive therapy shortly after starting glaucoma therapy. This suggests a prescribing trend toward earlier, more aggressive drug therapy to control pressure and minimize disease progression. We found that compliance with adjunctive therapy continues to be a problem for patients, which could be attributed to a number of treatment burden and economic factors.

No MeSH data available.


Related in: MedlinePlus

Patient identification process.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061175&req=5

f2-opth-8-1097: Patient identification process.

Mentions: Figure 2 shows the patient identification process for this analysis. In the present analysis, there were 16,486 beneficiaries with at least one prostaglandin analog prescription who met all requirements for eligibility. Table 1 shows that 5,933 (36%) had one or more pre-specified adjunctive therapies within 24 months from the start of the prostaglandin analog and had 12 months of follow-up available after the start of adjunctive therapy. For two-thirds of these patients (n=3,927), their initial adjunctive therapy was a nonselective beta-blocker, either alone (n=2,277) or as part of a fixed combination (n=1,650). The average age in all groups was just less than 70 years, and 51% of the patients were women.


Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs.

Schmier JK, Hulme-Lowe CK, Covert DW - Clin Ophthalmol (2014)

Patient identification process.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061175&req=5

f2-opth-8-1097: Patient identification process.
Mentions: Figure 2 shows the patient identification process for this analysis. In the present analysis, there were 16,486 beneficiaries with at least one prostaglandin analog prescription who met all requirements for eligibility. Table 1 shows that 5,933 (36%) had one or more pre-specified adjunctive therapies within 24 months from the start of the prostaglandin analog and had 12 months of follow-up available after the start of adjunctive therapy. For two-thirds of these patients (n=3,927), their initial adjunctive therapy was a nonselective beta-blocker, either alone (n=2,277) or as part of a fixed combination (n=1,650). The average age in all groups was just less than 70 years, and 51% of the patients were women.

Bottom Line: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population.The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011.There were 16,486 eligible beneficiaries.

View Article: PubMed Central - PubMed

Affiliation: Exponent, Alexandria, VA, USA.

ABSTRACT

Purpose: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population.

Methods: The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011. Patients who had one or more adjunctive therapy prescriptions during 24 months of follow-up were included. Patterns of adjunctive therapy use were identified and compared between patients who had one or two fills of the initial adjunctive therapy and those who had three or more.

Results: There were 16,486 eligible beneficiaries. Of these, 5,933 (36%) had one or more adjunctive therapies within 24 months from the start of the PGA, 82% of whom started adjunctive therapy within 12 months. About 28% of patients started adjunctive therapy with a fixed-combination product; 45% of these patients started within the first 30 days. Overall, a large number of patients (42%) required adjunctive therapy within 30 days. Twenty-five percent of patients had only one or two prescriptions of their initial adjunctive therapy; of these patients, 74% discontinued adjunctive therapy altogether.

Conclusion: Approximately 30% of patients starting glaucoma therapy will require adjunctive therapy within 1 year, and many receive a fixed-combination product as initial adjunctive therapy shortly after starting glaucoma therapy. This suggests a prescribing trend toward earlier, more aggressive drug therapy to control pressure and minimize disease progression. We found that compliance with adjunctive therapy continues to be a problem for patients, which could be attributed to a number of treatment burden and economic factors.

No MeSH data available.


Related in: MedlinePlus